sacituzumab tirumotecan (MK-2870) / Merck (MSD), Sichuan Kelun Pharma  >>  Phase 2
Welcome,         Profile    Billing    Logout  

12 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sacituzumab tirumotecan (MK-2870) / Merck (MSD)
OptiTROP-Lung01, NCT05351788: SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

Recruiting
2
110
RoW
SKB264, KL-A167, Carboplatin, Cisplatin
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Non-small Cell Lung Cancer
08/24
04/26
SKB264-Ⅱ-08, NCT05631262: SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors

Recruiting
2
366
RoW
SKB264, Docetaxel
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Selected Subjects With Advanced Solid Tumors
10/24
10/25
SKB264-Ⅱ-07, NCT05445908: SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer

Recruiting
2
175
RoW
SKB264, KL-A167
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Triple-negative Breast Cancer and HR+/HER2- BC
04/25
07/25
SKB264-II-06, NCT05642780: SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

Recruiting
2
184
Europe, Canada, US, RoW
SKB264, Pembrolizumab, Keytruda
Klus Pharma Inc., Myriad Genetics, Inc., Discovery Life Sciences, LLC, Ventana Medical Systems, Inc, Frontage Laboratories, Inc.
Solid Tumor
09/25
11/25
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Recruiting
2
498
Europe, RoW
SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate
Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
12/25
10/26
NCT06428409: A Clinical Study of MK-2870 Alone or With Chemotherapy to Treat Gastrointestinal Cancers (MK-9999-02A)

Recruiting
1/2
130
Europe, Canada, Japan, US, RoW
Sacituzumab tirumotecan, MK-2870, Fluorouracil (5-FU), Leucovorin (LV) or levoleucovorin, Rescue medication, Supportive care measures
Merck Sharp & Dohme LLC
Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
12/28
12/28
KEYMAKER-U04, NCT06483334: A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/)

Recruiting
1/2
98
Europe, Canada, US, RoW
Sacituzumab tirumotecan, MK-2870, SKB264, Enfortumab Vedotin, PADCEV™, Pembrolizumab, MK-3475, KEYTRUDA
Merck Sharp & Dohme LLC
Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
07/28
07/28
Keymaker-U06, NCT06445972: Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/)

Recruiting
1/2
90
Europe, US, RoW
Ramucirumab, Paclitaxel, MK-2870, SKB264, sacituzumab tirumotecan, sac-TMT
Merck Sharp & Dohme LLC
Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
12/26
10/28
KEYMAKER-06C, NCT06469944: Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

Recruiting
1/2
130
Europe, US, RoW
Pembrolizumab, MK-3475, Keytruda®, Sacituzumab Tirumotecan, MK-2870, SKB264, Capecitabine, XELODA, Leucovorin, calcium folinate, folinic acid, WELLCOVORIN®, Levoleucovorin, calcium levofolinate, levofolinic acid, FUSILEV®, 5-FU, ADRUCIL®
Merck Sharp & Dohme LLC
Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
01/27
04/29
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting
1/2
1300
Canada, US, RoW
SKB264
Klus Pharma Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer
08/25
07/26
TroFuse-027, NCT06637423: A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

Not yet recruiting
1/2
32
NA
Sacituzumab tirumotecan, SKB264, sac-TMT, MK-2870
Merck Sharp & Dohme LLC
Non-Muscle Invasive Bladder Cancer
06/26
11/26
KEYMAKER-U06 substudy 06B, NCT05319730: A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Recruiting
1/2
200
Europe, Japan, US, RoW
Paclitaxel, Irinotecan, Pembrolizumab, MK-3475, KEYTRUDA®, MK-4830, anti-immunoglobulin-like transcript 4 (anti-ILT4), Lenvatinib, MK-7902, LENVIMA®, Sacituzumab tirumotecan, SKB264, MK-2870, Antihistamine, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent)
Merck Sharp & Dohme LLC
Esophageal Squamous Cell Carcinoma
11/26
09/28

Download Options